USFDA24 Oct 2026, 03:00 pm
Lupin Goa Facility Inspected by US FDA
AI Summary
Lupin Ltd announced that the U.S. FDA has concluded an inspection at its manufacturing facility in Goa, India. The inspection, conducted from October 19-23, 2026, resulted in one observation on a Form-483. The company stated it will address the observation and respond to the FDA within the stipulated timeframe, reaffirming its commitment to CGMP standards across all facilities.
Key Highlights
- US FDA inspection concluded at Lupin's Goa manufacturing facility.
- One observation was noted on the Form-483.
- Lupin will respond to the FDA within the stipulated timeframe.
- Company remains committed to CGMP standards.
Price Impact
More from LUPIN